Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Goodwill & Intangibles (2022 - 2025)

NewAmsterdam Pharma's Goodwill & Intangibles history spans 4 years, with the latest figure at $407000.0 for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 23.78% year-over-year to $407000.0; the TTM value through Dec 2025 reached $407000.0, down 23.78%, while the annual FY2025 figure was $407000.0, 23.78% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $407000.0 at NewAmsterdam Pharma, down from $439000.0 in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $84.8 million in Q4 2022 and bottomed at $170000.0 in Q4 2023.
  • The 4-year median for Goodwill & Intangibles is $494000.0 (2024), against an average of $8.9 million.
  • The largest annual shift saw Goodwill & Intangibles plummeted 99.8% in 2023 before it skyrocketed 214.12% in 2024.
  • A 4-year view of Goodwill & Intangibles shows it stood at $84.8 million in 2022, then tumbled by 99.8% to $170000.0 in 2023, then surged by 214.12% to $534000.0 in 2024, then fell by 23.78% to $407000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Goodwill & Intangibles are $407000.0 (Q4 2025), $439000.0 (Q3 2025), and $470000.0 (Q2 2025).